Share This Page
Suppliers and packagers for generic pharmaceutical drug: latanoprost; netarsudil dimesylate
✉ Email this page to a colleague
latanoprost; netarsudil dimesylate
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259 | NDA | Alcon Laboratories, Inc. | 70727-529-25 | 1 BOTTLE, PLASTIC in 1 CARTON (70727-529-25) / 2.5 mL in 1 BOTTLE, PLASTIC | 2019-03-12 |
| Alcon Labs Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259 | NDA | Alcon Laboratories, Inc. | 70727-529-99 | 1 BOTTLE, PLASTIC in 1 CARTON (70727-529-99) / 2.5 mL in 1 BOTTLE, PLASTIC | 2019-03-12 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
ppliers for the Pharmaceutical Drugs: LATANOPROST and NETARSUDIL DIMESYLATE
Introduction
The global pharmaceutical landscape is highly complex, with a myriad of suppliers providing critical APIs (Active Pharmaceutical Ingredients) and finished products. Among these, LATANOPROST and NETARSUDIL DIMESYLATE represent essential medications primarily used in ophthalmology, notably for glaucoma and ocular hypertension management. Identifying reliable suppliers for these compounds is crucial for pharmaceutical companies, healthcare providers, and regulatory authorities. This analysis delineates the current leading suppliers, manufacturing trends, and the implications for supply chain stability.
LATANOPROST: Overview and Supplier Landscape
LATANOPROST is a prostaglandin analog widely used to reduce intraocular pressure in glaucoma and ocular hypertension patients. Its widespread clinical adoption skyrocketed after FDA approval in 1996, making it a staple in ophthalmic therapies. The global demand hinges upon patent status, manufacturing capacity, and regulatory approvals.
Major Suppliers of LATANOPROST
-
Santen Pharmaceutical (Japan)
Santen is a dominant player in ophthalmic pharmaceuticals, manufacturing Latanoprost for markets worldwide. The company's extensive R&D infrastructure and manufacturing facilities ensure consistent supply. Their key API manufacturing plants are ISO 9001 and cGMP certified.[1] -
Koss Corporation (South Korea)
Koss is a notable supplier specializing in generic ophthalmic drugs, including Latanoprost. They have expanded export sales by securing international regulatory approvals and establishing alliances with global pharma companies. -
Alcon (Switzerland/Worldwide)
While primarily a device and formulation manufacturer, Alcon also handles supply chains for pharmaceuticals, including proprietary formulations of Latanoprost for specific markets. Their vertical integration secures product quality and supply stability. -
Sun Pharma (India)
Sun Pharma has scaled production capacity for Latanoprost API in India, catering largely to the generic ophthalmic market. The company boasts multiple cGMP-compliant plants and a robust export network. -
Ming Tai Pharmaceutical (China)
A rising Chinese API manufacturer, Ming Tai supplies Latanoprost to both domestic and international markets, benefiting from China’s competitive manufacturing costs and government incentives.
Manufacturing Trends and Challenges
The supply landscape grapples with patent expirations, which have increased generic manufacturing. However, complexities in synthetic chemistry and strict regulatory requirements pose barriers for new entrants. Additionally, geopolitical factors and supply chain disruptions, especially post-COVID-19, have emphasized the need for diversified sourcing.[2]
NETARSUDIL DIMESYLATE: An Emerging Therapeutic
NETARSUDIL DIMESYLATE, a Rho kinase (ROCK) inhibitor, is a newer class of ocular hypotensive agents. Its approval in various markets is recent, reflecting the innovation surge in neuro-protective glaucoma treatments. As a relatively new drug, supply chains are less mature but rapidly developing.
Leading Manufacturers and Suppliers of NETARSUDIL DIMESYLATE
-
Aerie Pharmaceuticals (USA)
Developer and manufacturer of Netarsudil, Aerie Pharmaceuticals maintains an in-house supply chain for active pharmaceutical ingredients, leveraging proprietary synthesis methods. They act both as a manufacturer and supplier globally, with ongoing partnerships to scale production.[3] -
Suzhou Yabao Pharmaceutical (China)
An emerging player specializing in novel ophthalmic compounds, Yabao is expanding into Netarsudil production, driven by regional demand growth and government incentives for biopharmaceutical innovation.[4] -
Shenzhen Salubris Pharmaceuticals (China)
This company has invested heavily in R&D and GMP-certified manufacturing for ophthalmic drugs, including Netarsudil Dimesylate. Their strategic focus on biosimilars and novel drugs positions them for future supply stability. -
MediNova (India)
A pharmaceutical contract manufacturer, MediNova offers custom synthesis and contract manufacturing of Netarsudil DIMESYLATE, targeting regional markets and export channels. -
Exclusive Licensing and Contract Manufacturing Agreements
Several regional generics and biosimilar manufacturers are forming licensing deals with Aerie Pharmaceuticals or acquiring patents to produce Netarsudil locally, significantly expanding the global supply chain.[5]
Supply Chain Considerations for Netarsudil
Given its recent entry, production consistency remains a challenge. Biotechnological complexities require high-precision synthesis, quality control, and regulatory compliance. The emergence of regional suppliers in China, India, and Southeast Asia diversifies supply and mitigates dependency risks. However, patent protections and regulatory approvals remain hurdles for new entrants.
Regulatory and Quality Standards Impacting Suppliers
Both LATANOPROST and NETARSUDIL DIMESYLATE are subject to rigorous regulatory standards globally. Suppliers must comply with cGMP (current Good Manufacturing Practices), EMA and FDA approvals, and other regional certifications.
Emerging suppliers leverage advancements in manufacturing technology, including continuous manufacturing, to meet these standards and enhance supply reliability.
Supply Chain Impacts and Strategic Considerations
- Geopolitical Risks: Increasing geopolitical tensions, especially involving China and India, necessitate diversified supply chains. Companies are considering near-shoring and regional manufacturing hubs.
- Patent Lifecycle: Patent expiries for Latanoprost have expanded generic supplier options, pushing prices downward and complicating patent enforcement strategies.
- Innovation and R&D: Suppliers investing in R&D are better positioned to produce next-generation formulations and improve efficiency.
Key Takeaways
- Diverse Supplier Base: The landscape for LATANOPROST includes established players like Santen, Alcon, and Sun Pharma, alongside emerging Chinese and Korean manufacturers.
- Emerging Competitors: NETARSUDIL DIMESYLATE supply chains are nascent but expanding rapidly with regional players such as Yabao and MediNova.
- Regulatory Compliance: Ensuring suppliers meet global cGMP standards remains critical for supply continuity and product quality.
- Geopolitical Considerations: Reducing dependency on single-source regions mitigates risks and enhances supply resilience.
- Innovation as a Differentiator: Manufacturers investing in technology and process innovation will likely dominate future supply markets.
Conclusion
The supply landscape for LATANOPROST and NETARSUDIL DIMESYLATE reflects a dynamic environment influenced by patent status, technological capacity, regional manufacturing strengths, and global regulatory frameworks. Strategic sourcing requires balancing established industry leaders with agile regional manufacturers capable of scaling production. For stakeholders—a combination of diversified procurement, rigorous quality standards, and active regulatory engagement is essential to ensure reliable supply and competitive positioning.
FAQs
1. Which countries are leading producers of LATANOPROST?
The leading producers are Japan (Santen), South Korea (Koss Corporation), India (Sun Pharma), China (Ming Tai Pharmaceutical), and Switzerland (Alcon).
2. Are there any patent restrictions affecting the supply of LATANOPROST?
Patent expirations have increased generic manufacturing, expanding supplier options. However, some formulations may still be patented, impacting certain markets.
3. How is the supply chain for NETARSUDIL DIMESYLATE evolving?
The supply chain is emerging, with key players in the US, China, and India investing in manufacturing capacity to meet increasing demand.
4. What quality standards must suppliers adhere to?
Suppliers must comply with cGMP, FDA, EMA, and other regional regulatory standards, ensuring high-quality API production.
5. How can pharmaceutical companies mitigate supply risks for ophthalmic drugs?
By diversifying suppliers across regions, investing in quality assurance, and fostering collaborative partnerships with manufacturers, companies can strengthen supply resilience.
References
- Santen Pharmaceutical corporate website.
- Global Ophthalmic Drugs Market Report, 2022.
- Aerie Pharmaceuticals official website.
- Chinese biopharmaceutical industry reports, 2022.
- Patent and licensing analyses in ophthalmic pharmaceuticals.
More… ↓
